The CRO Forum is pleased to announce that Allegra van Hövell-Patrizi, Chief Risk Officer of Aegon N.V., has been elected CRO Forum Chair for 2021. Allegra has been the Chief Risk Officer of Aegon N.V. since 2016. She has over 20 years’ experience in the financial services
PRESS RELEASE NEW CHAIRPERSONS 2021
The CRO Forum is pleased to announce that Allegra van Hövell-Patrizi, Chief Risk Officer of Aegon N.V., has been elected CRO Forum Chair for 2021.
Allegra has been the Chief Risk Officer of Aegon N.V. since 2016. She has over 20 years’ experience in the financial services industry, both working for large international companies and in an advisory capacity. Educated in France, she has extensive international experience, having worked in the UK, Benelux, Czech Republic, France, Germany, Italy, Romania and Russia.
Among the youngest ever to be elected as a Partner at McKinsey, Allegra was a member of the leadership team for banking, wholesale banking, asset management and insurance. In addition, she contributed to a number of initiatives aimed at shaping the financial landscape in Europe. Prior to working in the insurance sector, Allegra has held various positions at the UK asset management company F&C Investments.
Allegra’s election as Chairperson follows her tenure as Vice Chairperson since July 2019. Commenting on her new role as Chairperson in 2021, Allegra said: “I’m excited and honoured to take on this role, and I’m looking forward to engaging with my peers on risk management best practices in these unprecedented times – combining a pandemic with the exit of a major economy from the EU and the review of the major European solvency regime for insurance.”
Andreas Märkert, Chief Risk Officer of Hannover Re and Vice Chair of the CRO Forum in 2020, will continue serving his two-year term as Vice Chair in 2021.
Andreas is the Chief Risk Officer of Hannover Re Group and managing director of the division Group Risk Management. He has been with Hannover Re since 2004 in various roles including the oversight for Hannover Re’s economic capital model and capital allocation. Andreas holds a PhD in Mathematics and is member of the German Actuarial Society.
Peter Giger, Group Chief Risk Officer of Zurich Insurance Group has been elected Vice Chair of the CRO Forum.
Peter is the Group Chief Risk Officer of Zurich Insurance. Prior to being appointed as Zurich’s Group Chief Risk Officer and member of the Executive Committee, effective October 1, 2019, he served from 2014 to 2018 as the head of the Swiss Financial Market Supervisory Authority FINMA’s insurance division. During that time he also served as FINMA’s deputy CEO and a member of its executive team. From 2002 to 2014 he held executive leadership roles at Zurich, including CFO General Insurance from 2010 to 2014. Prior to that he headed Structured Finance at Swiss Re from 1999 to 2002. Peter began his career at Zurich, holding a series of management positions between 1992 and 1999.
The CRO Forum would like to thank Frieder Knüpling for chairing the CRO Forum in 2020.
Source URL:Read More The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.
Acquire this Domain You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.
About Us We are Internet Investors, Developers, and Incubators- operating a content network of several thousand sites while federating 20+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $15M+ in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Discover our work!
Monitoring tools, like cookies, are in use. Continued access to this site indicates your acceptance of Cookie settingsAcceptNo
GDPR & CCPA Notices
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.